Diligence memo · auto-generated · as of July 2, 2026
Cardiodx Inc
Cardiodx Inc looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Cardiodx Inc operates in Biotechnology, based in REDWOOD CITY.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cardiodx Inc has raised $174M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $57M on 2011-02-17.
Most recent recorded round closed around 2017-01-05.
Valuation (modeled)modeled
Provath models Cardiodx Inc at approximately $742M (range $56M–$2.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.36× the median modeled value of Series C Biotechnology companies in 2016–2018 (41 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 9.5 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 3.6× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 96% of Biotechnology peers (4293 compared).
Modeled value ranks above 86% of those peers.
Closest niche peers: Genesis Biopharma, Inc, Alder Biopharmaceuticals Inc, Ideaya Biosciences, Inc., Stoke Therapeutics, Inc., 4D Molecular Therapeutics Inc.
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.